NCT06676774 Effect of Intranasal Oxytocin on Emotion Recognition and Acute Psycho-Social Stress-induced Cortisol Increase in Patients With Central Diabetes Insipidus and Healthy Controls
| NCT ID | NCT06676774 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | University Hospital, Basel, Switzerland |
| Condition | Arginine Vasopressin Deficiency |
| Study Type | INTERVENTIONAL |
| Enrollment | 42 participants |
| Start Date | 2025-05-16 |
| Primary Completion | 2027-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 42 participants in total. It began in 2025-05-16 with a primary completion date of 2027-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to investigate the potential beneficial effects of intranasal oxytocin compared to placebo on emotion recognition and acute psychosocial stress in patients with arginine vasopressin deficiency compared to matched healthy controls.
Eligibility Criteria
Inclusion criteria healthy controls 1. Adult healthy volunteers 2. Matched for age, sex, BMI, and oestrogen replacement/menopause/hormonal contraceptives to patients. 3. No medication, except hormonal contraception Inclusion criteria 1. Adult patients with a confirmed diagnosis of AVP deficiency based on accepted criteria6 2. Stable hormone replacement therapy for at least three months with desmopressin and, in case of additional anterior pituitary deficiencies, with the respective substitution therapies. Exclusion criteria 1. Participation in a trial with investigational drugs within 30 days 2. Active substance use disorder within the last six months 3. Consumption of alcoholic beverages \>15 drinks/week 4. Current or previous psychotic disorder (e.g., schizophrenia spectrum disorder) 5. Pregnancy and breastfeeding within the last eight weeks
Contact & Investigator
Mirjam Christ-Crain, Prof. Dr.
PRINCIPAL INVESTIGATOR
University Hospital, Basel, Switzerland
Frequently Asked Questions
Who can join the NCT06676774 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Arginine Vasopressin Deficiency. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06676774 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06676774 currently recruiting?
Yes, NCT06676774 is actively recruiting participants. Contact the research team at mirjam.christ-crain@ubs.ch for enrollment information.
Where is the NCT06676774 trial being conducted?
This trial is being conducted at Basel, Switzerland.
Who is sponsoring the NCT06676774 clinical trial?
NCT06676774 is sponsored by University Hospital, Basel, Switzerland. The principal investigator is Mirjam Christ-Crain, Prof. Dr. at University Hospital, Basel, Switzerland. The trial plans to enroll 42 participants.